EGFR: Tale of the C-terminal tail

Protein Science

Volumn 22, Issue 7, 2013, Pages 995-999

  Gajiwala, Ketan S ^a  

^a PFIZER INC   (United States)

Author keywords

C terminal tail; Conformation; EGFR; Kinase; Regulation

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PHOSPHOTRANSFERASE;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CHEMICAL MUTAGENESIS; ENZYME ACTIVITY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN STRUCTURE; REGULATORY MECHANISM;

ANIMALS; HUMANS; MODELS, MOLECULAR; PEPTIDE FRAGMENTS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84881303407     PISSN: 09618368     EISSN: 1469896X     Source Type: Journal    
DOI: 10.1002/pro.2283     Document Type: Article

References (21)

1. Schlessinger J (2000) Cell signaling by receptor tyrosine kinases. Cell 103:211-225.
2. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, Lemmon MA, Sliwkowski MX, Ward CW, Yokoyama S (2003) An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell 12:541-552.
3. Liu P, Cleveland TEt, Bouyain S, Byrne PO, Longo PA, Leahy DJ (2012) A single ligand is sufficient to activate EGFR dimers. Proc Natl Acad Sci USA 109:10861-10866.
4. Endres NF, Das R, Smith AW, Arkhipov A, Kovacs E, Huang Y, Pelton JG, Shan Y, Shaw DE, Wemmer DE, Groves JT, Kuriyan J (2013) Conformational coupling across the plasma membrane in activation of the EGF receptor. Cell 152:543-556.
5. Stamos J, Sliwkowski MX, Eigenbrot C (2002) Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem 277:46265-46272.
6. Red Brewer M, Choi SH, Alvarado D, Moravcevic K, Pozzi A, Lemmon MA, Carpenter G (2009) The juxtamembrane region of the EGF receptor functions as an activation domain. Mol Cell 34:641-651.
7. Kim Y, Li Z, Apetri M, Luo B, Settleman JE, Anderson KS (2012) Temporal resolution of autophosphorylation for normal and oncogenic forms of EGFR and differential effects of gefitinib. Biochemistry 51:5212-5222.
8. Gotoh N, Tojo A, Hino M, Yazaki Y, Shibuya M (1992) A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor. Biochem Biophys Res Commun 186:768-774.
9. Zhang X, Gureasko J, Shen K, Cole PA, Kuriyan J (2006) An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell 125:1137-1149.
10. Jura N, Endres NF, Engel K, Deindl S, Das R, Lamers MH, Wemmer DE, Zhang X, Kuriyan J (2009) Mechanism for activation of the EGF receptor catalytic domain by the juxtamembrane segment. Cell 137: 1293-1307.
11. Arkhipov A, Shan Y, Das R, Endres NF, Eastwood MP, Wemmer DE, Kuriyan J, Shaw DE (2013) Architecture and membrane interactions of the EGF receptor. Cell 152:557-569.
12. Hubbard SR (2009) The juxtamembrane region of EGFR takes center stage. Cell 137:1181-1183.
13. Thiel KW, Carpenter G (2007) Epidermal growth factor receptor juxtamembrane region regulates allosteric tyrosine kinase activation. Proc Natl Acad Sci USA 104:19238-19243.
14. Wood ER, Truesdale AT, McDonald OB, Yuan D, Hassell A, Dickerson SH, Ellis B, Pennisi C, Horne E, Lackey K, Alligood KJ, Rusnak DW, Gilmer TM, Shewchuk L (2004) A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor offrate, and receptor activity in tumor cells. Cancer Res 64:6652-6659.
15. Bublil EM, Pines G, Patel G, Fruhwirth G, Ng T, Yarden Y (2010) Kinase-mediated quasi-dimers of EGFR. FASEB J 24:4744-4755.
16. Pines G, Huang PH, Zwang Y, White FM, Yarden Y (2010) EGFRvIV: a previously uncharacterized oncogenic mutant reveals a kinase autoinhibitory mechanism. Oncogene 29:5850-5860.
17. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137.
18. Mustafa M, Mirza A, Kannan N (2011) Conformational regulation of the EGFR kinase core by the juxtamembrane and C-terminal tail: a molecular dynamics study. Proteins 79:99-114.
19. Solca F, Dahl G, Zoephel A, Bader G, Sanderson M, Klein C, Kraemer O, Himmelsbach F, Haaksma E, Adolf GR (2012) Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker. J Pharmacol Exp Ther 343:342-350.
20. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F, Rettig WJ, Meyerson M, Solca F, Greulich H, Wong KK (2008) BIBW2992, an irreversible EGFR/ HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 27:4702-4711.
21. Sorkin A, Mazzotti M, Sorkina T, Scotto L, Beguinot L (1996) Epidermal growth factor receptor interaction with clathrin adaptors is mediated by the Tyr974-containing internalization motif. J Biol Chem 271: 13377-13384.